Clinical

FDA clears perioperative Keytruda + Padcev for all patients with muscle-invasive bladder cancer, establishing a new cisplatin-independent standard of care.

Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer treatment and survivorship.

Phase 3 TRANSCEND shows setmelanotide cuts BMI and hunger in acquired hypothalamic obesity, signaling a new targeted option after hypothalamic injury.

Stefanie Houseknecht, PharmD, discusses patient education, financial barriers, and pharmacy's expanding role in precision lung cancer care.

This episode, titled 'Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression,' features Nadege Gunn, MD discussing the following critical questions: 1. How do you risk-stratify your patients, and what clinical or metabolic factors most reliably predict progression? 2. What does the literature tell us about the relationship between meaningful weight loss and fibrosis regression, and how does that inform your thinking about weight-loss therapy as a hepatic intervention?

In 'Screening MASH Upstream: Building a Practical, Scalable Algorithm for the Real World,’ Nadege Gunn, MD delves into the following critical question: 1. There is growing interest in screening for MASH further upstream. What would a practical, scalable screening algorithm look like in your view, and what are the limitations of that approach?

The first half of 2026 saw the FDA approve 5 notable first-in-class therapies across obesity, AML, kidney disease, hearing loss, and bladder cancer.

This segment explores the growing role of genomic testing and multidisciplinary coordination in the management of hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores deeper clinical interpretations of the SERENA-6 trial, particularly focusing on circulating tumor DNA dynamics and their relevance in hormone receptor–positive, HER2-negative metastatic breast cancer.

Explore the biggest FDA PDUFA decisions expected in 2026, including gedatolisib, iberdomide, zidesamtinib, bepirovirsen, and anito-cel.

Jennifer Sheng, MD, discusses how consistent follow-up, patient education, and lifestyle interventions improve breast cancer survivorship care.

As presented at EHA 2026, AGAVE-201 showed no significant bone health safety signals with axatilimab in chronic graft-versus-host disease (cGVHD).

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Christina Poh confirmed that the disconnect between provider and patient experiences of shared decision-making resonates strongly with what she observes in clinical practice, noting that while care teams tend to focus on efficacy and side effect profiles, the questions patients ask most frequently are logistical in nature, underscoring that closing this gap requires not only better communication, but also more robust patient navigation support, improved coordination between academic and community settings, and clinical trial designs that better reflect the real-world follicular lymphoma patient population.

Christina Poh discussed how she counsels patients on follicular lymphoma as a chronic, relapsing-remitting disease that is highly treatable, with many patients living for years or even decades with good quality of life, while being transparent that current standard-of-care treatments are unlikely to be curative, framing this honest, forward-looking conversation as the foundation for a long-term therapeutic partnership built on realistic expectations and shared planning.

The expanded approval, based on the phase 3 WIL-33 trial, gives children with von Willebrand disease access to routine bleeding prophylaxis.

Large biobank study suggests a polygenic risk score may improve prediction of idiopathic pulmonary fibrosis diagnosis and outcomes.

Carl Regillo, MD, on missed wet AMD injections, treatment switching, and how gene therapy could ease chronic burden.

INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.

The AGAVE-201 analysis found no significant bone health concerns with axatilimab in chronic GVHD, showing stable biomarkers and no increased fractures.

Secondary analysis of the STAR trial finds hypoglossal nerve stimulation cut hypoxic burden by 76.6%, even in some AHI-defined nonresponders.

Payer delays and unpredictable coverage stall mental health meds, worsening symptoms, work performance, and ER risk while forcing clinicians into inefficient trial-and-error care.

Clinicians weigh generics versus new psychiatric meds, emphasizing evidence for treatment-resistant cases, staying current, and balancing costs, side effects, and whole-person care.

The FDA advisory committee supports Moderna’s mRNA-1010 flu vaccine for adults 50-plus, with an August 5 PDUFA decision pending for mFlusiva.

Learn how tumor and liquid biopsy testing fits care—plus insurance hurdles, turnaround delays, and the push for faster NGS results.